Literature DB >> 11755437

Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.

M A Pfaller1, A F Ehrhardt, R N Jones.   

Abstract

Continuing problems of antimicrobial resistance have prompted the initiation of several surveillance programs. Few, if any, of these programs focus on community-acquired respiratory tract infections seen in routine office-based practices. The Respiratory Surveillance Program (RESP; 1999-2000) in 674 community-based physician office practices in the United States determined the frequency of potential bacterial pathogens including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in patients diagnosed clinically with community-acquired pneumonia, acute exacerbations of chronic bronchitis, and sinusitis throughout all 9 US census/geographic regions. Susceptibility to the penicillins (ampicillin, penicillin), oral cephalosporins, fluoroquinolones (gatifloxacin, levofloxacin, ciprofloxacin), macrolides (erythromycin, azithromycin, clarithromycin), tetracycline, and trimethoprim/sulfamethoxazole was determined by reference methods. Patients were required to have a culturable focus of infection, and specimens were immediately sent to a reference laboratory. Among 22,689 total specimens (610 community-acquired pneumonia, 4,779 acute exacerbation of chronic bronchitis, 16,213 sinusitis, 1,087 other), H influenzae was the most commonly isolated organism from patients with community-acquired pneumonia (38%) and acute exacerbation of chronic bronchitis (35%) in all nine geographic regions. S pneumoniae was isolated in 18% of community-acquired pneumonia cases, 13% of acute exacerbation of chronic bronchitis cases, and 11% of sinusitis cases. M catarrhalis was most commonly isolated from the nasopharynx of patients with sinusitis (29%). High-level resistance to penicillin (2 microg/mL or greater; 16% overall) and the macrolides (32% to 35%) among S pneumoniae varied both with site of infection and with geographic region. The greatest resistance was observed among isolates from the nasopharynx of patients with sinusitis and from patients from the East South Central or South Atlantic regions of the United States. Although the susceptibility of H influenzae and M catarrhalis to the tested antimicrobials did not vary with the type of infection, beta-lactamase-mediated resistance to ampicillin among H influenzae ranged from 15% in New England to 32% in the East South Central region. The fluoroquinolones were highly active against these cultured isolates from community-acquired respiratory tract infection patients, with >99% of all S pneumoniae, H influenzae, and M catarrhalis strains susceptible to gatifloxacin (MIC(90), 0.5 microg/mL) and levofloxacin (MIC(90), 2 microg/mL). The extended-spectrum fluoroquinolones appear well suited for community-acquired respiratory tract infection therapy, including pathogens other than pneumococcus, H influenzae, and M catarrhalis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11755437     DOI: 10.1016/s0002-9343(01)01025-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.

Authors:  Sanjay Sethi; John Breton; Brian Wynne
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.

Authors:  Laura Lawrence; Paul Danese; Joe DeVito; Francois Franceschi; Joyce Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

3.  Evaluation of a multiplexed PCR assay for detection of respiratory viral pathogens in a public health laboratory setting.

Authors:  David J Marshall; Erik Reisdorf; Gerda Harms; Edward Beaty; Michael J Moser; Wai-Ming Lee; James E Gern; Frederick S Nolte; Pete Shult; James R Prudent
Journal:  J Clin Microbiol       Date:  2007-10-10       Impact factor: 5.948

4.  Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil.

Authors:  Jose-Luis Alvarez-Sala; Peter Kardos; Jesús Martínez-Beltrán; Pilar Coronel; Lorenzo Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.

Authors:  Charles R Dean; Shubha Narayan; Denis M Daigle; JoAnn L Dzink-Fox; Xiaoling Puyang; Kathryn R Bracken; Karl E Dean; Beat Weidmann; Zhengyu Yuan; Rakesh Jain; Neil S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 6.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Sialylation of lipooligosaccharides promotes biofilm formation by nontypeable Haemophilus influenzae.

Authors:  W Edward Swords; Miranda L Moore; Luciana Godzicki; Gail Bukofzer; Michael J Mitten; Jessica VonCannon
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 8.  Acute rhinosinusitis : a pharmacoeconomic review of antibacterial use.

Authors:  Jean-Blaise Wasserfallen; Françoise Livio; Giorgio Zanetti
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections.

Authors:  Heinz Burgmann; Bernd Mayer; Arno Lukas; Friedrich Kumbein; Rainer Oberbauer
Journal:  Wien Med Wochenschr       Date:  2003

Review 10.  Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management.

Authors:  Don Hayes; Keith C Meyer
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.